Diabetes (type 2) - canagliflozin: evaluation report
01. Pre-meeting Briefing prepared by NICE
02. Pre-meeting Appendices prepared by NICE
03. Submission from the technology manufacturer Janssen
04. Erratum Submission from the technology manufacturer Janssen
05. NICE request to the manufacturer for clarification on their submission
06. Manufacturer clarification response
07. Consultee submission - Association of British Clinical Diabetologists (ABCD) and Royal College of Physicians (RCP)
08. Consultee submission - Royal College of Nursing
09. Clinical expert personal perspective - Matthews
10. Clinical expert statement Sathyapalan
11. Evidence Review Group report prepared by Southampton Health Technology Assessments Centre (SHTAC)
12. Erratum Evidence Report prepared by Southampton Health Technology Assessments Centre (SHTAC)
13. Manufacturer factual accuracy check of Evidence Group Report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *
Diabetes (type 2) - canagliflozin: evaluation report
24 February 2014 (13.83 Mb 43 sec) |
This page was last updated: 06 March 2014